Various companies have made notable headlines recently, revealing important stock movements and developments in the market. Intel, despite facing significant struggles, saw a slight rebound with a 1.2% increase toward the end of the year. However, the outlook for 2024 remains concerning, as projections suggest a potential decline of more than 60%, marking what could be its worst performance historically.
On the other hand, Nvidia, a key player in the artificial intelligence sector, experienced a 2.3% drop as traders looked to cash in profits as the trading year wrapped up. Despite this decrease, Nvidia’s stock has surged over 170% throughout the year, positioning it as one of the top performers in the S&P 500.
In other news, Sangamo Therapeutics retained the rights to a hemophilia gene therapy product. Biohaven Pharmaceuticals saw its stock rise by 4.4% following the disclosure that board member John Childs purchased 29,000 shares, bringing his total ownership to approximately 6.5 million shares.
NutriBand’s shares increased by 12.7% after the company announced expectations for an expedited review process of its abuse-deterrent opioid patch, AVERSA Fentanyl, potentially leading to regulatory approval by late 2025. This announcement follows the extension of its Chinese patent to Macau. Lastly, Zivo Bioscience’s stock rose nearly 3% after investor Mark Strome purchased an additional 75,000 shares, increasing his stake in the biotechnology research firm to 10%.